34
Participants
Start Date
January 4, 2021
Primary Completion Date
July 15, 2022
Study Completion Date
May 4, 2023
GHR-LRX
GHR-LRX was administered by SC injection.
Debreceni Egyetem Klinikai Kozpont, Debrecen
Memorial Sloan Kettering Cancer Center, New York
East-Tallinn Central Hospital, Tallinn
Clinical Center of Serbia, Belgrade
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan
Clinical Center of Vojvodina, Novi Sad
Endocrinology Associates, Inc, Columbus
Cleveland Clinic, Cleveland
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos, Kaunas
Tartu University Hospital, Tartu
Vaidoto Urbanaviciaus Individuali imone, Alytus
Palm Research Center Inc., Las Vegas
Cedars-Sinai Medical Center, Los Angeles
Oregon Health & Science University (OHSU), Portland
I.M. Sechenov Moscow First State Medical University, Moscow
Massachusetts General Hospital, Boston
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma
Pauls Stradins Clinical University Hospital, Riga
Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii, Warsaw
Uniwersytecki Szpital Kliniczny, im. Jana Mikulicza-Radeckiego we Wroclawiu,, Wroclaw
Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw
Centrul Medical Unirea Bucuresti, Endocrinologie, Bucharest
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY